SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$38.04 USD
+1.17 (3.17%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $38.00 -0.04 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
SWTX 38.04 +1.17(3.17%)
Will SWTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SWTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SWTX
SpringWorks (SWTX) Rises More Than 40% in a Year: Here's Why
SpringWorks (SWTX) Completes NDA Submission for Mirdametinib
SWTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Tops Revenue Estimates
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
SpringWorks (SWTX) Surges More Than 80% in 3 Months: Here's Why
Other News for SWTX
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
SpringWorks Therapeutics (SWTX) Shares Cross Below 200 DMA
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Springworks Therapeutics (SWTX) and SAGE Therapeutics (SAGE)
Barclays Sticks to Its Buy Rating for Springworks Therapeutics (SWTX)
TD Cowen Remains a Buy on Springworks Therapeutics (SWTX)